StandardX, a deep tech startup building an isotope refinery, has raised £10 million seed funding to increase production of rare isotopes for medicine and energy. The round was led by Vsquared Ventures and East X Ventures, with additional backing from firstminute capital, the UK Innovation and Science Seed Fund, managed by Future Planet Capital, Brevan Howard Macro Venture and Geometry. Funding will support first production of medical isotopes and accelerate progress towards a resilient supply for cancer diagnostics and treatment, next-generation immunotherapy and life-saving research.
Isotopes, a form of a chemical element with specific properties, are among the world’s rarest and most sought-after materials and underpin innovation across healthcare, energy and other critical sectors. Global production capacity is constrained, fragile and fragmented, reliant on a patchwork of ageing facilities and output-limited machines concentrated in a handful of locations. Supply is increasingly unable to meet today's need, let alone scale to tomorrow's demand in advanced medicine for cancer diagnostics and treatment. NHS cancer waiting time targets are consistently missed, with only 69.6% of patients receiving treatment within 62 days of an urgent referral in May 2026, well below the 85% target, which has not been met since December 2015. Isotopes enabling a new generation of cancer treatments, particularly targeted alpha therapies, are so scarce that clinical trials have been paused or delayed across the United Kingdom, Europe and beyond.
StandardX is developing an isotope refinery that aims to turn this chronic scarcity into a reliable and abundant supply. A proprietary accelerator system replaces today’s patchwork of narrow, isotope-specific infrastructure. Deployable and built on a standard industrial footprint, each machine is capable of manufacturing the full isotope portfolio at commercial scale, supporting a distributed model of supply with production sited close to demand. Production will begin with isotopes for cancer diagnosis and therapy, servicing the supply hospitals rely on today and the isotopes drug-makers need to invent tomorrow's treatments, some of which are not commercially available at any scale today. StandardX plans to supply first isotopes to a medical research partner in 2027.
The same accelerator platform will later scale to isotopes for other advanced industries, including tritium, the scarce fuel that fusion energy runs on. Only 25kg of tritium exists globally today but tens of kilograms are needed to run a single fusion power plant for a year, and StandardX has already signed agreements with leading fusion developers to manufacture tritium to support their missions. Founded in 2025 by nuclear engineers Richard Pearson, CEO, and Ross Allen, CTO, StandardX has built a team of 15 scientists, engineers and operators from organisations including SpaceX, The London Clinic, Oxford University, Cambridge University, Fermilab and the UK Atomic Energy Authority. Seed funding will grow the team, secure the first industrial site in London, advance the design and build of the first accelerator-based isotope refinery system, and enable pilot production of isotopes with distribution to a medical partner next year, ahead of industrial-scale production from 2029.
Isotopes underpin the next era of innovation across several key sectors, but all share the same constraints around supply. Shortages are most acute in cancer medicine, already impacting patients today, and stalling progress in the development of next-generation treatments. This problem will only get worse, with new cancer cases projected to increase 67% by 2050. So we're building the platform the world needs to address this.
StandardX began with a problem: isotope supply limited by legacy infrastructure. This raise moves us from concept into engineering, physics into hardware, and conversations into delivery. Our immediate priority is our industrial site in London, where we will deploy our first isotope refinery system and work closely with clinicians and researchers to start building a reliable supply chain.
Radiopharma is approaching an extraordinary inflection point, but isotope supply simply hasn’t kept pace. StandardX is building a fundamentally flexible production platform that can move with the science, from the isotopes medicine needs today to those that will define the next generation of cancer treatment. We believe it can become critical infrastructure for the next era of radiopharma and Richard and Ross have the rare technical expertise and ambition to build it. Being located in London puts StandardX at the heart of one of Europe’s leading ecosystems for cancer research and clinical trials.
StandardX is tackling a supply problem that matters enormously today in medicine, while building a platform that could become critical infrastructure for fusion tomorrow. What makes the opportunity particularly compelling is the asymmetry: StandardX can build a valuable isotope business without relying on fusion timelines, but if fusion scales, tritium could become one of the defining industrial bottlenecks of the sector. With only a tiny global inventory today and substantial quantities ultimately required to fuel commercial fusion systems, we believe StandardX has the potential to play a critical role in securing that supply.
